ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ブリンシドフォビル

Brincidofovir

HCID 483477
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
444805-28-1
標準SMILES
CCCCCCCCCCCCCCCCOCCCOP(=O)(O)CO[C@H](CO)Cn1ccc(N)nc1=O
InChIKey
WXJFKKQWPMNTIM-VWLOTQADSA-N
分子式
C27H52N3O7P
平均分子量
561.7 g/mol
単同位体質量
561.354288

概要

Brincidofovir is a hydroxypyrimidine.

名称と識別子

優先名称
Brincidofovir
IUPAC
[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid
現地名
ブリンシドフォビル
英語名
CMX 001
分子式
C27H52N3O7P
分子量
561.69

名称と別名

Brincidofovir444805-28-1CMX001HDP-CidofovirHexadecyloxypropyl-cidofovirCMX-001HDP-CDVHexadecyloxypropyl cidofovirTembexaCMX 001[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acidCidofovir Hexadecyloxypropyl Ester
名称をさらに表示
ブリンシドフォビル({[(2S)-1-(4-アミノ-2-オキソ-1,2-ジヒドロピリミジン-1-イル)-3-ヒドロキシプロパン-2-イル]オキシ}メチル)[3-(ペンタデシルオキシ)プロポキシ]ホスフィン酸ブリンシドホビル[(S)-1-[(1,2-ジヒドロ-2-オキソ-4-アミノピリミジン-1-イル)メチル]-2-ヒドロキシエチルオキシ]メチルホスホン酸4-オキサノナデカン-1-イルBrincidofovir (CMX001)CS-2275HDP-HPMPCCMX 001 - Bio-X ?CMX001(Brincidofovir)Fampridine Impurity 23
6794O900AX1-O-hexadecylpropanediol-CDVDTXSID60196190Phosphonic acid, p-(((1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, mono(3-(hexadecyloxy)propyl) esterbrincidofovirum((2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl)oxymethyl-(3-hexadecoxypropoxy)phosphinic acidRefChem:57400DTXCID70118681

物性

構造計算による物性補完中

XLogP
4.9
極性表面積
144 Ų
水素結合供与体数
3
水素結合受容体数
7
回転可能結合数
26
重原子数
38
形式電荷
0
複雑度
721

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
SolubilityPractically insoluble
Human Drugs · 3 件

Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

物理化学的性質

融点
177 ° · > 177° C (dec.)
沸点
688.6 · 688.6±65.0 °C(Predicted)
比重(密度)
1.17 · 1.17±0.1 g/cm3(Predicted)
貯蔵温度
-20 °C · Hygroscopic, -20°C Freezer, Under inert atmosphere
溶解性
DMSO (Slightly, Sonicated), Ethanol (Slightly, Heated, Sonicated), Methanol (Sli
外見
個体
酸解離定数(Pka)
2.4 · 2.40±0.10(Predicted)
色
ホワイトからオフホワイト
安定性
吸湿性
InChIKey
WXJFKKQWPMNTIM-VWLOTQADSA-N
SMILES
P(CO[C@H](CO)CN1C(=O)N=C(N)C=C1)(=O)(O)OCCCOCCCCCCCCCCCCCCCC

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

毒性情報

Hepatotoxicity · 1 件

In preregistration clinical trials of brincidofovir as prevention of cytomegalovirus and adenovirus infection in adults and children after hematopoietic stem cell transplantation (HSCT), serum aminotransferase elevations were more frequent with brincidofovir (22%) than placebo (16%) treatment, the usual rate of hepatic enzyme elevations being high after HSCT. ALT elevations above 5 times the upper limit of normal (ULN) arose in 1.8% vs 1.4% , and one of 269 brincidofovir recipients discontinued therapy because of ALT elevations above 10 times ULN. The ALT and AST elevations arose early as brincidofovir was given only 2 or 3 times, on days 1 and 8 and in some trials day 21 of treatment. In the same trials mild-to-moderate elevations in serum bilirubin arose in 6.5% of those on brincidofovir vs 5.9% of placebo recipients, again reflecting the high rate of bilirubin elevations in patients after HSCT. In small studies in healthy human volunteers abnormalities of liver tests were not observed. Since approval of brincidofovir, there have been no instances of smallpox infection that qualified for its use. However, the emergence of mpox infection shortly after its approval has led to its use for this non-approved indication. Aminotransferase elevations were frequent in the mpox virus infected subjects treated with brincidofovir but were invariably asymptomatic, transient and without symptoms or concurrent bilirubin elevations. Thus, the total clinical experience with use of brincidofovir is limited. While transient serum aminotransferase elevations have been reported with its use, there have been no reports of clinically apparent liver injury linked to brincidofovir therapy.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
WGK 3
Hazard Classifications
Acute Tox. 3 OralCarc. 2Repr. 2Skin Sens. 1
ストレージクラス
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects

化学と産業

薬理情報

ATC Code · 2 件

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

Protein BindingBrincidofovir is >99% protein-bound in plasma, although the specific protein(s) to which it binds have not been elucidated.
Pharmacodynamics · 1 件

The pharmacologically active agent resulting from brincidofovir metabolism, cidofovir diphosphate, has an exceedingly long duration of action that allows for it to be dosed once weekly. The entirety of a brincidofovir smallpox treatment consists of only two doses, on days 1 and 8, which seemingly reduces the risk of adverse reactions. Regimens involving a longer duration of administration (i.e. more than a single dose on days 1 and 8) have been shown to increase mortality compared to placebo and should therefore be avoided. Brincidofovir is considered a potential human carcinogen and has demonstrated the potential to cause infertility - as such, its use should be restricted to situations in which it is absolutely necessary.

Mechanism of Action · 1 件

Brincidofovir is a pro-drug comprising [cidofovir] conjugated to a lipid molecule - the lipid component mimics an endogenous lipid, lysophosphatidylcholine, which allows the molecule to hijack endogenous lipid uptake pathways to enter infected cells. Following uptake, the lipid molecule is cleaved to generate cidofovir, which is then phosphorylated to generate the active antiviral compound, cidofovir disphosphate. The antiviral effects of cidofovir diphosphate appear to be the result of two distinct mechanisms. Mechanistic studies using recombinant vaccinia DNA polymerase suggest that it inhibits orthopoxvirus DNA polymerase-mediated DNA synthesis. In addition, cidofovir is an acyclic nucleotide analogue of deoxycytidine monophosphate - cidofovir diphosphate can therefore be incorporated into the growing viral DNA chain and consequently slow the rate of viral DNA synthesis.

Biological Half-LifeThe mean terminal half-lives of brincidofovir and its pharmacologically active metabolite, cidofovir diphosphate, are 19.3 hours and 113 hours, respectively.
Metabolism/Metabolites

関連反応

2 件
反応記録を作成
HRID 624683 の反応式
HRID 624683生成物として
HRID 1046038 の反応式
HRID 1046038生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
444805-28-1
PubChem CID
483477
DTXSID
DTXSID60196190
ChEMBL
CHEMBL203321
ChEBI
CHEBI:231032
UNII
6794O900AX
Nikkaji
J2.075.976C
· 1 件

Brincidofovir is a pro-drug of [cidofovir] and as such must undergo some basic metabolic reactions to become pharmacologically active. Upon entering the target cell, the phosphodiester bond of brincidofovir is hydrolyzed to generate cidofovir, which is then phosphorylated to generate the active agent: cidofovir diphosphate. The specific enzyme(s) responsible for this reaction have not been elucidated, but _in vitro_ findings suggest sphingomyelin phosphodiesterase plays a major role in the initial hydrolysis of brincidofovir. There are two major inactive metabolites of brincidofovir, CMX103 and CMX064, which are generated via carboxylation of the terminal carbon followed by several cycles of CYP-mediated oxidative reactions and fatty acid oxidation. These reactions are mediated, at least in part, by CYP4F2.

MeSH Pharmacological Classification · 1 件

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.

Absorption, Distribution and Excretion · 4 件

The oral bioavailability of brincidofovir is 13.4% in its tablet formulation and 16.8% in its suspension formulation. Following oral administration, the Cmax and AUCtau of brincidofovir were 480 ng/mL and 3400 ng·hr/mL, respectively. The Cmax and AUCtau of the active metabolite, cidofovir diphosphate, were 9.7 pg/106 cells and 1200 pg·hr/106 cells, respectively. Maximum plasma concentrations (Tmax) of brincidofovir are reached at approximately 3 hours post-administration, while maximal plasma concentrations for cidofovir diphosphate are reached at approximately 47 hours post-administration.

Brincidofovir is eliminated as metabolites in both the urine (~51%) and feces (~40%).

The apparent volume of distribution of brincidofovir is 1230 L.

The apparent clearance of brincidofovir in healthy adult patients is 44.1 L/h.